Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine

NCT00970879 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 430

Last updated 2013-01-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of cotrimoxazole prophylaxis in prevention of malaria during pregnancy in HIV-infected women, compared to intermittent preventive treatment with mefloquine.

Conditions

  • Malaria in Pregnancy
  • HIV Infections

Interventions

DRUG

cotrimoxazole

800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery

DRUG

mefloquine

mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy

Sponsors & Collaborators

  • Sidaction

    collaborator OTHER
  • Saint Antoine University Hospital

    collaborator OTHER
  • National University Hospital, Cotonou

    collaborator OTHER
  • Université d'Abomey-Calavi

    collaborator OTHER
  • Ministry of Health, Benin

    collaborator OTHER_GOV
  • Institut de Recherche pour le Developpement

    lead OTHER_GOV

Principal Investigators

  • Marcel D Zannou, Professor · Cotonou University Hospital & Faculté des Sciences de la Santé, Benin

  • Pierre-Marie Girard, Professor · Saint Antoine Hospital, Assistance Publique-Hôpitaux se Paris

  • Michel Cot, MD, PHD · Institut de Recherche pour le Developpement

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-07-31
Completion
2012-12-31

Countries

  • Benin

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00970879 on ClinicalTrials.gov